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Hormone therapy at early post-
menopause increases cognitive 
control-related prefrontal activity
Romuald Girard1,2, Elise Météreau1,2, Julie Thomas1,2, Michel Pugeat2,3, Chen Qu1,4 &  
Jean-Claude Dreher1,2
Clinical data have been equivocal and controversial as to the benefits to the brain and cognition 
of hormone therapy (HT) in postmenopausal women. Recent reevaluation of the role of estrogens 
proposed that HT may effectively prevent the deleterious effects of aging on cognition, and reduces 
the risks of dementia, including Alzheimer’s disease, if initiated early at the beginning of menopause. 
Yet, little is known about the effects of HT on brain activation related to cognitive control, the ability to 
make flexible decisions in relation to internal goals. Here, we used fMRI to directly test for a modulation 
of sequential 17β estradiol (2 mg/day) plus oral progesterone (100 mg/day) on task switching-related 
brain activity in women at early postmenopause. The results showed that HT enhanced dorsolateral 
prefrontal cortex recruitment during task switching. Between-subjects correlation analyses revealed 
that women who engaged more the dorsolateral prefrontal cortex showed higher task switching 
performance after HT administration. These results suggest that HT, when taken early at the beginning 
of postmenopause, may have beneficial effect on cognitive control prefrontal mechanisms. Together, 
these findings demonstrate that HT can prevent the appearance of reduced prefrontal cortex activity, a 
neurophysiological measure observed both in healthy aging and early dementia.
Fundamental behavioral and neurophysiological data in rodents and monkeys provide strong evidence for the 
existence of a window of opportunity allowing a neuroprotective effect of estradiol on the brain and beneficial 
effects on cognitive functions, when estrogens are initiated near the time of cessation of ovarian function, but 
not after a long period of ovarian hormone deprivation1,2. In humans, the effects of HT on brain and cogni-
tion are much more controversial. A number of studies reported that HT may prevent the deleterious effects of 
aging on cognition in early post-menopausal women, and reduces the risks of dementia, Alzheimer’s disease and 
mild cognitive impairment3,4, while HT administrated in postmenopausal women well beyond midlife does not 
improve cognitive skills5,6. Other studies have found that initiation of HT more than a few years after menopause 
is associated with an unchanged or increased risk of dementia and age-associated cognitive decline5,6. Moreover, 
Women’s Health Initiative Memory Study reported that postmenopausal HT with conjugated equine estrogens, 
when prescribed to women 65 years and older, produced deficits in cognitive functioning7,8.
The time between onset of menopause and when the treatment was initiated has been proposed to be a key 
factor explaining part of these discrepant observations1,2. According to the ‘critical time window’ hypothesis, HT 
effectively decreases cognitive decline in aging when it is initiated around the time of menopause, but not if it is 
administered decades later. Although there is a crucial need to test this hypothesis in women, the challenge is the 
difficulty of running a long clinical trial to test whether HT administrated early at the time of menopause effec-
tively improves cognitive functions many years later.
Here, asking a different question, we aimed to investigate the impact of HT on a neurocognitive function 
known to be impaired later in life. Using a unique crossover placebo-controlled design, we carefully selected early 
postmenopausal women and investigated the effects of HT on brain activity related to cognitive control, a key 
function allowing flexible mental set-shifting, selection of actions and control of behavior in response to envi-
ronmental context and internal goals. Since the magnitude of normal, age-related declines in cognitive control 
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in women in their 50 s is very minimal, it has been a challenge to detect a behavioral index of estrogen benefits 
in early postmenopausal women2. In contrast, a neuroimaging approach focusing on brain regions subserving 
cognitive control has the potential to be sensitive enough to detect the effects of HT in the absence of behavioral 
change. Such experimental approach has previously proven useful to reveal estrogen effects on brain regions 
subserving verbal memory function, even in the absence of behavioral change9–12.
Here, we studied the effects of sequential 17β estradiol plus progesterone on brain activity engaged dur-
ing task switching, by carefully selecting early postmenopausal women in a counterbalanced, randomized, 
crossover, double-blind and placebo-controlled design (Fig. 1, Table S1). Women took HT and a placebo dur-
ing 8 weeks each. None of the women had ever taken HT before inclusion in the study. This unique crosso-
ver placebo-controlled design controlled for a number of confounding factors contributing to the discrepancies 
observed in the estrogen–cognition literature, including differences in the estrogen compounds administered, 
their route of administration, HT duration, age at HT initiation, inclusion of naive users HT13.
During fMRI acquisition, women performed a task switching paradigm twice (once under placebo, once under 
HT), which consisted in alternating between two letter discrimination tasks based on the color of the letters14 (Fig. 2A). 
Flexibly switching between cognitive operations is known to engage a bilateral prefronto-parietal network in 
healthy young individuals14–17 and older subjects have disruptively low activity in this network, particularly 
in prefrontal areas18. Based on these findings, we hypothesized that HT, as compared to placebo, will induce 
a relative increase in dorsolateral prefrontal activity during task switching in women at early post-menopause. 
Moreover, we tested whether this potential increased prefrontal cortex activity with HT plays a beneficial effect 
on task switching performance.
Results
Behavioral results during scanning. Mean responses times (RT) (Fig. 2C) and error rate (ER) (Fig. 2D) 
were assessed with a repeated ANOVA with condition (task switching, control) and treatment (HT, placebo) as 
factors. Subjects were slower (F(1, 11) = 37.8, p < 0.001) and made more errors (F(1, 11) = 11.6, p < 0.001) during 
task switching than during the control condition (average of tasks A and B performed separately), suggesting 
that the switching condition engaged additional cognitive processes compared to those needed for the control 
condition. There was no main effect of treatment on RT (F(1,11) = 0.4, p = 0.5) or error rates (F(1,11) = 0.6, p = 0.4), 
nor interaction between conditions and treatment types (RT: F(1,11) = 0.7, p = 0.4;error rate: F(1,11) = 0.002, 
p = 0.96). Another ANOVA including treatment (HT versus Placebo) and type of trials (switch versus repeat) 
Figure 1. Experimental design. Early postmenopausal women were enrolled in a double blind, randomized, 
placebo-controlled crossover study. They took a daily pill of either HT (respectively placebo) for two cycles of  
28 days each, followed by two consecutive months of placebo (respectively HT). For the first 11 days of a 
‘restored’ menstrual cycle (under HT), pills contained 17β estradiol (2 mg/day). From the 12th to the 21th day, 
the pills contained an addition of 100 mg/day of progesterone. This was followed by a week washout period. 
This cycle was repeated for a second month (see yellow rectangle). After these two months, a new cycle started: 
women receiving HT first were administrated with a placebo containing 2 mg/day of inactive substance for the 
first 11 days and 102 mg/day for the following 10 days. This cycle was repeated during a last cycle of 28 days. The 
order of receiving HT and placebo was randomly assigned and counter-balanced. Blood samples were collected 
at the beginning of the study and on each day of scanning (once under HT and once under Placebo).
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was performed separately for each task switching condition. This analysis revealed a task switch cost on RT (F(1, 
11) = 18.8, p < 0.001) and error rates (F(1, 11) = 7.9, p < 0.01) (i.e. higher RT and error rates for switch compared 
to repeat trials), and no main effect of treatment on RT (F(1, 11) = 0.0035, p = 0.95) and error rates (F(1, 11) = 0.3, 
p = 0.5). The interaction between switch cost and treatment was not significant (RT: F(1, 11) = 0.001, p = 0.97; error 
rate: F(1, 11) = 2.2, p = 0.1). The absence of treatment effect on reaction time or error rate is in line with findings 
from the large KEEPS trial19, which reported no cognitive benefit of estrogens in early postmenopausal women.
Estradiol levels. The day of inclusion in the study (i.e. before HT or placebo treatment), plasma estradiol 
level was 29.9 ± 23.7 pmol/L, confirming women’s perimenopausal status. This baseline estradiol level was signif-
icantly lower than when women were under HT (142.7 ± 70 pmol/L) (F(1, 11) = 34.6, p < 0.001) and did not differ 
significantly from when they were under placebo (20.6 ± 2.9 pmol/L) (F(1, 11) = 2.12, p = 0.17). When directly 
comparing estradiol concentrations on the two scanning days, HT increased plasma estradiol level relative to 
placebo (F(1, 11) = 34.6, p < 0.001) (Fig. 2B).
fMRI results. Brain regions engaged by task switching compare to control, regardless of treatment type. We 
first searched for brain regions engaged by “task switching” relative to the control condition (Fig. 2, Table 1). 
Increased BOLD response was mainly observed in a bilateral fronto-parietal network including the bilateral dor-
solateral prefrontal cortex (DLPFC), anterior lateral PFC (i.e., aLPFC), the anterior cingulate cortex and the infe-
rior lateral prefrontal cortex. The bilateral inferior (iPC) and superior (sPC) parietal cortex, the anterior insula 
(BA 47) and cerebellar regions also showed higher activity during task switching relative to control. The engage-
ment of this bilateral prefronto-parietal network is consistent with previous fMRI studies assessing task switching 
Figure 2. Tasks and behavioral results. (A) Women responded to visually presented letters by pressing response 
buttons with their right or left hand. Each condition was cued by a distinct written instruction displayed at the 
beginning of the run. In task-switching condition, subjects had to switch between two letter-discrimination tasks 
depending upon the color of the letter. If the letter was red, subjects performed a vowel–consonant discrimination 
task (vowel: right button; consonant: left button). If the letter was green, subjects performed a case discrimination 
task (upper case: right; lower case: left). In two conditions used for control, women performed each of these two 
vowel/consonant and upper/lower case discrimination tasks in separate blocks of trials. The control was the 
average of these two simple discrimination tasks. Stimuli appeared with fixed timing (inter stimuli interval = 3 s, 
stimulus duration = 800 ms) in a pseudo-randomized order. (B) Estradiol measures. Estradiol level (pmol/L) 
measured on the two days of the scanning sessions under HT and Placebo. (C) Mean and SEM response time. 
During the task switching condition (i.e. both switch and repeat trials from the task switching condition), 
subjects were significantly slower than in the control condition (p < 0.001). A switch cost was also observed when 
comparing switch trials to repeat trials (p < 0.001). (D) Mean and SEM Error rate. Z error cost was observed 
in women regardless of treatment type, that is, women made more errors in switch compared to repeat trials 
(p < 0.01) and control (p < 0.001) trials.
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using the same paradigm in healthy subjects14–18. Conversely, relative deactivation in a large anterior medial 
frontal cortex region was observed in the opposite comparison (control > task switching), consistent with the 
default mode network (Fig. S1A).
Direct comparison between HT and placebo during task switching. When directly comparing HT administration 
relative to placebo (p < 0.001, uncorrected), women showed increased BOLD signal during task switching relative 
to control in a bilateral frontal network including the right DLPFC (BA 46), the ventro-lateral prefrontal cortex 
and the anterior cingulate cortex (BA 24) (all: p < 0.05, SVC FWE corrected). The inferior frontal junction/ante-
rior insula bilaterally (right: p < 0.05, FWE cluster-wise corrected) showed an increased activity, as well (Fig. 4, 
Table 2). Interestingly, none of the parietal regions engaged in the main effect of task reached statistical signifi-
cance in this direct comparison (p > 0.05).
Direct statistical comparison between treatment types showed that placebo, relative to HT (p < 0.001, 
uncorrected) elicited higher activity in the anterior medial frontal cortex, middle and posterior cingulate gyrus 
(p < 0.05, FWE cluster-wise corrected), striatum, bilateral superior and inferior parietal cortex (p < 0.05, FWE 
cluster-wise corrected), temporal cortex and occipital regions (p < 0.05, FWE cluster-wise corrected) (Fig. S1B, 
Table S2).
Correlation between brain activity and behavioral performance. To restrict our analysis to the brain regions 
showing higher BOLD response under HT in the task switching condition relative to control (Fig. 4A), we created 
an inclusive binary mask (p < 0.05, uncorrected). We then applied it to the brain regions showing a positive corre-
lation between BOLD activity and the percent correct performance in task switching under HT (p < 0.05, uncor-
rected). The betas from the activated voxels under HT were extracted at the peak-voxel in the DLPFC (x = 39, 
y = 5, z = 64 and x = − 39, y = 8, z = 61) (Fig. 4C) and in the ACC (x = 3, y = 26, z = 22) (p < 0.05, uncorrected) 
to plot the correlation. Moreover, direct comparison between correlation coefficients from the two conditions 
showed that women who engaged more the left and right DLPFC had better performance in the task switching 
condition after HT administration than after placebo (Fisher z-transformation, Z = 1.95, p < 0.05). No negative 
correlation between percent correct performance in task switching and the brain network engaged under HT 
relative to control (p > 0.05).
Discussion
The beginning of post-menopause provides a unique model to study how naturally low endogenous baseline 
estrogen levels influence cognitive control-related brain activity. The key question addressed by the current study 
was to investigate the modulatory effect of HT on early post-menopausal women’s brain activity while engaged 
in a cognitive control paradigm. The ability to dynamically switch between tasks is a critical function allowing 
flexible behavior and seemless transitions between cognitive operations. It has been difficult to distinguish the 
effects of aging and changes in gonadal steroid hormones levels on brain activity because endocrine and neural 
senescence overlap in time and are mechanistically intertwined in complex feedback loops. Our careful selection 
of women in a specific age range (around 52 years old) allowed us to pinpoint the specific effect of HT on brain 
activity during task switching. Our neuroimaging findings indicate an increased lateral prefrontal activity associ-
ated with HT administration, relative to placebo (Fig. 4A and B). A number of neuroimaging studies investigating 
cognitive control and working memory functions have demonstrated reduced or abnormal pattern of prefrontal 
activity in healthy older subjects20,21 and in early dementia22. Our results showed that among postmenopausal 
women taking HT, those increasing the most activity of the dorsolateral prefrontal cortex were also the ones 
who performed better in task switching (Fig. 4C). The stronger between-subject positive correlation between 
dorsolateral prefrontal activation and percent correct task switching performance observed with HT compared 
to placebo, indicates that such increased BOLD signal is beneficial for cognitive performance.
Figure 3. Brain regions engaged by task switching compare to control, regardless of treatment type. Data 
for brain regions commonly activated by task switching relative to control, regardless of hormonal status, were 
overlaid onto a 3D-rendered brain (Display threshold: voxel-wise p < 0.001, uncorrected; cluster-wise p < 0.05, 
FWE corrected).
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Our current crossover placebo-controlled design has a number of advantages because it is controlled for a 
number of factors contributing to the discrepancies in the estrogen–cognition literature. These factors include 
differences in the estrogen compounds used, their route of administration, HT duration, age at HT initiation, 
inclusion of both past and current users HT and cyclic versus continuous regimens13. In contrast, in our study, 
none of the women had taken HT before and each crossover woman serves as her own control using the exact 
same dose, duration and mode of administration of HT.
There has been a lack of human neuroimaging studies investigating the neurofunctional influence of HT on 
cognitive control in early post-menopausal women and, to the best of our knowledge, our study is the first to inves-
tigate the impact of estrogen plus progesterone on brain activity during a task switching paradigm. Our findings 
extend to the cognitive control domain a number of neuroimaging results obtained in postmenopausal women 
using estradiol alone and investigating working memory functions11,12 or retrieval of words from memory23,24, 
indicating that estrogen enhances prefrontal functions. Consistent with this effect, studies combining functional 
neuroimaging and pharmacological manipulation inducing ovarian hormone suppression in healthy young 
women demonstrated decreased activation in prefrontal cortex, anterior cingulate and medial frontal gyrus dur-
ing verbal encoding9 and the Wisconsin Card Sorting test25. These effects were reversed when estradiol levels 
Main effect of the task switching > control condition
Anatomical Structure 
x y z T value(Broadmann’s area)
Frontal
 Left Superior frontal gyrus (BA 6) − 21 − 7 61 3.78
 Right Superior frontal gyrus (BA 9)* 18 47 40 5.75
 Left Middle frontal gyrus (BA 44)* − 45 20 37 11.66
 Right Middle frontal gyrus (BA 45)* 51 29 34 7.43
 Left Inferior frontal gyrus (BA 45)* − 45 35 4 11.66
 Right Inferior frontal gyrus (BA 47)* 45 38 − 8 7.60
 Left Precentral gyrus (BA 6) − 27 − 10 58 3.90
 Left Putamen* − 27 − 1 7 7.45
 Left SMA (BA 6) − 3 − 1 61 6.99
Parietal
 Left Superior parietal lobule (BA 7)* − 21 − 64 58 6.16
 Right Superior parietal lobule (BA 40)* 42 − 55 55 7.09
 Left Inferior parietal lobule (BA 7)* − 33 − 55 49 9.65
 Left Precuneus (BA 7)* − 12 − 70 46 6.63
 Right Angular gyrus (BA 7)* 36 − 58 46 5.89
Temporal
 Left Middle temporal gyrus (BA 20) − 45 − 22 − 17 6.16
 Right Inferior temporal gyrus (BA 37)* 60 − 61 − 8 5.04
 Right Temporal pole (BA 38)* 54 11 − 5 3.97
 Right Fusiform gyrus (BA 20) 39 − 22 − 20 6.64
Occipital
 Left Superior occipital gyrus (BA 19)* − 18 − 73 40 7.11
 Left Middle occpital gyrus (BA 18) − 36 − 91 − 8 4.05
 Left Inferior occipital gyrus (BA 19)* − 42 − 79 − 11 7.33
 Right Inferior occipital gyrus (BA 19) 39 − 88 − 5 4.58
 Left Calcarine gyrus (BA 19)* − 21 − 73 7 5.70
 Right Calcarine gyrus (BA 17) 21 − 61 10 6.10
Cerebellum
 Left Anterior lobe (BA 37)* − 24 − 43 − 29 7.56
 Right Anterior lobe (BA 37)* 18 − 58 − 26 8.43
 Left Posterior lobe (BA 19)* − 30 − 67 − 23 6.17
 Left Vermis* − 3 − 46 7 6.93
 Right Vermis* 0 − 55 − 8 6.14
Cingulate cortex
 Right Middle cingulate cortex (BA 23) 9 − 31 34 5.27
Insula
 Right Insula (BA 47)* 42 23 − 2 6.47
Table 1.  Brains regions showing increased activity during task switching compared to control condition. 
The coordinates are given within the framework standardized stereotaxic brain area atlas of Talairach and 
Tournoux (1988). All areas were significant at p < 0.001, uncorrected, *p < 0.05 FWE cluster-wise corrected.
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returned to normal levels10,25. Consistent with these neuroimaging studies, preclinical data also attest to a neu-
roregulatory role of estradiol on the prefrontal cortex. In female monkeys, estrogen increases spine density and 
plasticity in the PFC26 while ovariectomy decreases spine density in the PFC of female rats27. Potential neurophys-
iological bases of this effect are that the PFC is one of the highest estrogen binding sites in the female brain, with 
estradiol PFC concentrations being approximately twice higher compared with the temporal lobe and seven times 
higher compared with the hippocampus28.
Our fMRI results indicate that neuroimaging is efficient to detect effects of HT not yet visible with behavioral 
measures2. Indeed, the neurofunctional differences we observed between HT and placebo were evident despite a 
lack of direct behavioral differences in task switching performance between HT and placebo, indicating that fMRI 
can detect effects of sequential estrogen plus progesterone on prefrontal cortex not yet apparent with behavioral 
measures. This absence of task switching differences between HT and placebo at the behavioral level is consistent 
with the absence of substantial effect of HT on executive function or episodic memory in recently menopausal 
women2,29,30. These clinical trials in midlife women are also in agreement with results from larger trials in older 
women2,31. However, reports from the longitudinal Study of Women’s Health Across the Nation suggest that nat-
ural menopause has a slight effect on some aspects of cognitive function that may be time limited. That is, women 
Figure 4. Direct comparison between HT and placebo during task switching relative to control.  
(A) Significantly greater activation after HT administration compared with placebo during task switching 
blocks relative to control (Display threshold, p < 0.005, uncorrected). The activation maps are overlaid on 
coronal sections of a structural template MRI. The color bars represent t values. (B) Mean and SEM of the 
contrast values in functional clusters of interest during task switching condition when comparing HT and 
placebo. From left to right, in the right dorsolateral prefrontal cortex, the right ventro-lateral prefrontal cortex, 
the anterior cingulate cortex and the inferior frontal junction/anterior insula. (C) Positive correlation between 
% correct performance and parameter estimates in right and left DLPFC in the task switching > control 
conditions in women under HT.
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who initiated HT after enrollment but before their final menstrual period and then discontinued the HT had a 
beneficial cognitive effect, whereas women who initiated HT after the final menstrual period had a detrimental 
effect on cognitive performance32.
A number of neuroimaging data demonstrated neuroregulatory effects of sex steroid hormones on working 
memory or verbal episodic memory functions in women. However, these effects were, by definition indirect and 
have largely been inferred from changes occurring during the normal menstrual cycle, after the administration 
of ovarian hormones to surgically menopausal women or in pharmacological models of menopause10,25,33. In 
contrast, the current results directly indicate that in women with naturally low estradiol level, early HT initiation 
increases lateral PFC cognitive control-related activity.
The absence of behavioral effect of HT in the relatively young women (around 50 y.o) we tested was expected 
from the literature. Since the magnitude of normal, age-related declines in cognitive control in women in their 
50 s is very minimal, it has been a challenge to detect a direct behavioral index of estrogen benefits in early post-
menopausal women2. This is not only true in the domain of cognitive control, but also in the domain of working 
memory, which engages the same brain circuitry (dorsolateral prefrontal and intra-parietal region). Moreover, 
practice effects are likely to mask more subtle effect of HT on cognitive control function. Subjects followed a 
training session on the day before each scan to minimize performance differences across HT and placebo condi-
tions. Thus, our use of overlearned cognitive material likely limited our ability to detect performance changes due 
to HT because of ceiling effects. Not only the behavioral performance did not change on average with hormonal 
state, but also the variance of these measures was likewise similar across the HT and placebo conditions. Thus, on 
the basis of the present data, we cannot rule out the possibility that cognitive impairments with placebo would 
have been seen with other cognitive tasks if they had not been overlearned.
Note, that it can in fact be considered an advantage to observe no change in task switching performance 
between HT and placebo in women in their 50’s. Indeed, if women had shown worst performance in task switch-
ing either under placebo or under HT while engaging more robustly the same fronto-parietal network with 
HT, this would have obscured the neuroimaging interpretation. Similar problems of interpretation in neuro-
imaging occur for example when comparing healthy subjects with patients with schizophrenia, who generally 
perform more poorly than healthy controls in terms of working memory20. In such situation, it is difficult to 
interpret the changes in brain activation between patients and controls as being truly due to the disease rather 
than to the change in performance. Similarly, in the current study, if we had observed differences in task switching 
Hormone therapy > Placebo
Anatomical Structure (Broadmann’s 
area) x y z T-value
Frontal
Right Middle frontal gyrus (BA 46)** 42 35 40 4.13
Left Inferior frontal gyrus (BA 48) − 36 23 10 4.19
Right Inferior frontal gyrus (BA 48)** 33 26 16 4.51
Left Paracentral lobule (BA 4) − 15 − 28 67 3.49
Right Rolandic Operculum (insula)* 63 − 4 10 4.52
Cingulate
Left Anterior cingulate cortex (BA 24)** 0 14 28 3.70
Right Middle Cingulate gyrus (BA 24) 3 8 37 3.63
Hippocampus
Left Hippocampus − 18 − 25 − 8 3.57
Thalamus
Left Thalamus − 15 − 16 10 4.31
Temporal
Right Superior temporal gyrus (BA 48) 63 2 4 4.38
Right Middle temporal gyrus (BA 20) 63 − 40 − 11 3.50
Right Inferior temporal gyrus (BA 20) 57 − 28 − 20 4.18
Left Temporal Pole (BA 48) − 48 8 − 8 4.81
Right Temporal Pole (BA 20) 39 11 − 29 3.83
Right Heschls gyrus (BA 48)* 60 − 7 7 4.48
Midbrain
Right Vermis (BA 30) 6 − 40 − 17 3.57
Insula
Left Insula (BA 48) − 39 5 − 2 3.55
Table 2.  Brains regions showing increased activity after hormone therapy compared with placebo during 
task switching blocks relative to control. The coordinates are given within the framework standardized 
stereotaxic brain area atlas of Talairach and Tournoux (1988). All areas were significant at p < 0.001 
uncorrected, *p < 0.05 FWE cluster-wise corrected, **p < 0.05 SVC FWE corrected.
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performance between HT and placebo, it would have been difficult to know whether between groups differences 
in brain activation would have been due to HT alone or to the change in behavioral performance.
Studying the impact of HT on the neural substrates of cognitive control in early post-menopausal women has 
important implications for health and neurological diseases because decline in executive functions are central to 
theories of normal age-related changes in cognition20,34 and because of potential benefits of HT on reducing the 
risks of neurodegenerative disorders, known to disrupt prefrontal executive functions22,35. Executive functions 
deficits are frequent in neurodegenerative disorders such as Alzheimer’s disease, frontotemporal degeneration, 
and its subtype frontotemporal dementia36–38. Executive deficits may also predict conversion from mild cogni-
tive impairment to Alzheimer’s disease39–41 and the progression of FTD42,43. Recent cross-sectional studies have 
reported a relative increased activity during task performance in prefrontal regions in older subjects or patients 
with neurodegenerative diseases, including frontotemporal dementia or Alzheimer’s disease, when comparing 
to younger or healthy age-controlled subjects44–47. However, this increased pattern activity was not observed 
over time in longitudinal studies and may reflect compensatory effect to maintain cognitive function45. Since 
cognitive flexibility is an outcome variable which declines with age and predicts dementia later in life37–41,43, our 
results suggest a beneficial effect of HT on cognitive control brain function if HT starts early at the beginning of 
post-menopause.
Our results demonstrate short-term effects of HT on brain activity during task switching. Several caveats 
need to be mentioned. First, the sample size is relatively low for a fMRI study. However, given the inclusion cri-
teria (recruitment of healthy hormone therapy naive early postmenopause women) were very stringent and the 
repeated measures design required (each woman had to be scanned twice), this is understantable. In fact, such 
sample size conforms to the literature on hormonal effect in women48–51. Second, the long-term effects of the same 
intervention, repeated month after month, may or may not be similar throughout the early postmenopause and 
into the late postmenopause. Third, effects may apply to healthy postmenopausal women but not necessarily to 
postmenopausal women with neurodegenerative disorders. Finally, the effects observed on brain activity may or 
may not be associated with effects that are clinically observable.
Our study, combining pharmacological manipulation, endocrinology and functional brain imaging in healthy 
women, helps to specify the effect of hormonal modulation on brain activity. Our results have implications for 
understanding brain responses benefits of sequential estradiol plus progesterone therapy in midlife women. 
Together, our study provides evidence of a neurofunctional modulation of cognitive control mechanisms by HT 
and establishes a neurobiological foundation for understanding the beneficial impact of gonadal steroid hor-
mones on the brain regions engaged in task switching functions.
Methods
Subjects. Fifteen healthy, right-handed, non-smoking women in stage + 1a of early postmenopause (accord-
ing to STRAW + 10 terminology)52 were carefully selected through advertisement in local newspapers. Three of 
them were excluded from the analyses because of problems encountered during scanning. The mean age of the 
twelve remaining women was 51.8 ± 2.1 years old (range 48–55 years old). Women were all at the end of their 
menopause transition (9.6 ± 5.7 [range = 6–24] months of amenorrhea after the last menstrual period) at the time 
of their inclusion. By definition, menopause transition ends when a woman has gone 12 months without having 
her period. We chose to initiate HT early in this group of women (the time between the last menses and HT initi-
ation was less than a year) to maximally take advantage of a possible beneficial effect of HT on cognitive control. 
None of the women had ever taken hormonal therapy before inclusion in the study. All women were french native 
speakers with at least a high school level of education. Women were initially screened by phone interview, and 
then underwent a full clinical interview and a physical exam (performed by M.P). Exclusion criteria included any 
past or present use of estrogen or progestin, current or previous mental disorders, depressive tendency assessed 
by the Beck Depression Inventory (DBI), pathological gambling assessed by the South Oaks Gambling Screen 
(SOGS), hypertension, diabetes, elevated cholesterol, breast cancer and MRI contraindications. The study was 
approved by the local ethics committee (Centre Léon Bérard, Lyon, France) and written informed consent was 
obtained from all subjects in accordance with the principles of the Declaration of Helsinki.
Hormone and Placebo treatment. Our choice of the hormonal treatment (sequential estrogen-plus-progestin) 
was done to reproduce the hormonal environment of physiological early postmenopause53,54 and also on the fact 
that unopposed estrogen (the supplementation of endogenous estrogens without a progestagen) can result in endo-
metrial hyperplasia, a precursor to endometrial cancer. Each woman received HT and a placebo in a random and 
counter-balanced order (half of women started the experiment with 2 months of HT while the other half started it after 
taking a placebo for 2 months) (Fig. 1, Table S1). For the first 11 days of a ‘restored’ menstrual cycle, women took a daily 
pill containing 17β estradiol (2 mg/day). From the 12th to the 21st day, women took 100 mg/day of oral progesterone 
in addition to estradiol. This was followed by a week washout period. This same cycle was repeated during a second 
month. The group of women receiving HT during the first 2 months of the experiment took placebo pills on week 8 for 
11 days and for the following 10 days. After another week washout period, the placebo cycle was repeated. The visual 
aspect and dose of the placebo pills was exactly the same as those with active treatment. None of the women included in 
the analysis experienced menstrual cycle recovery after each cycle of estradiol and progesterone therapy. All pills were 
manufactured by the Pharmacy Division of the ‘Groupement Hospitalier Est’ (Bron, France). Women were asked to 
take their pills every day at the same time. On the scanning days, women took their pills one hour before the session.
Stimuli and Task. On each scanning day, women had to respond to visual stimuli consisting of single alpha-
betical red or green letters (vowels or consonants, lower or upper case) presented at the center of the screen, by 
pressing on one of two response buttons held in each hand (Fig. 3A). Each fMRI session was composed of 5 runs 
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with 3 conditions (24 trials in each condition). A cue displaying a distinct written instruction was provided at the 
beginning of each condition. In the vowel-consonant discrimination condition (task A), subject had to press the 
right button if the letter was a vowel and the left button if the letter was a consonant. In the case discrimination 
condition (task B), subject had to press the right button if the letter was upper case and the left button if the letter 
was lower case. In these two conditions, the color of the letter was irrelevant and changed pseudo-randomly. The 
control condition was composed of the mean of these two discrimination tasks [(A + B)/2] (i.e., the two single 
tasks averaged together).
In the task switching condition, subject had to perform one of the two tasks mentioned above according to 
the color of the letter, red letters indicating the vowel–consonant discrimination condition while green letters 
indicated the case discrimination condition. Switch trials were defined as trials in which subjects had to alternate 
from the previous task (from task A to task B or from Task B to task A). Repeat trials were defined as trials in 
which subjects repeated the same task (from task A to task A or from task B to task B). In the three conditions, the 
Inter Stimuli Interval (ISI) was 3 s and the stimulus duration was 800 ms. The letters used in the different condi-
tions were taken among the following set of letters (i.e., upper or lower cases, red or green): c, d, f, h, k, m, p, r, t, 
v, a, e, i, o, u, y. All conditions were constructed by pseudo-randomly choosing among this set of letters that were 
equated for the number of vowels/consonants, upper/lower case letters, red/green letters and left/right responses. 
Each run was pseudo-randomly ordered according to a Latin square design, so that each condition appeared only 
once at different serial positions within a run and control and switch conditions alternated. The order of runs was 
also counterbalanced across subjects.
fMRI Acquisition. Subjects were scanned twice, on the 39th day of each treatment stage, i.e. on the 11th day 
of the 2nd and of the 4th month (Fig. 1). High-resolution images were obtained with a 1.5 T Siemens Magnetom 
Sonata Maestro Class MRI System (Siemens, Munich, Germany). Two higher order shimming procedures were 
completed: the first covering the whole brain, whereas the second covered the orbitofrontal region. Five func-
tional time series of 100 whole-brain images functional scans were performed with an EPI T2*-weighted sequence 
(TR/TE = 2500/60 ms, flip angle = 90°; FOV = 22 cm, acquisition matrix = 64 × 64, slices thickness = 4 mm). An 
axial anatomic T1-weighted sequence (TR/TE = 1970/3.93 (ms), inversion time TI = 1100 ms, FOV = 256 mm, 
acquisition matrix = 256 × 256, slice thickness = 1mm, number of slices = 26) along the anterior commissure/
posterior commissure (i.e., AC/PC) line and covering the whole brain was also acquired. For hormonal measures 
and fMRI data analyses, see Supplemental methods.
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Supplementary Methods 
 
Hormonal measures 
 Four venous blood samples were drawn to measure estradiol plasma level: one 
before the study to check the perimenopausal status, one on the first day of inclusion in 
the study and the last two before each fMRI session. The samples were centrifuged, 
aliquoted, and stored at -70°C until time of assay. Serum 17b-estradiol was measured by 
tritiated radioimmunoassay after diethylether extraction. The anti-estradiol antibody was 
raised by immunization of rabbit with estradiol-6-CMO-BSA. The antibody cross-reacted 
by 8.8% with 6-OH-estradiol, 3.0% with 16-ceto-17b-estradiol, 1% with estrone, 0.15% 
with estriol, 0.4% with 17a-estradiol, 0.1% with ethynyl-estradiol and <0.001% with 
testosterone or 17a-OH-progesterone. The detection limit was 11 pmol/L and the inter-
assay coefficient of variation was 12.1% for 21 pmol/L, 6.0% for 100 pmol/L and 9.4 % 
for 169 pmol/L. An ANOVA was performed with HT/placebo as independent factor to test 
the difference between estradiol levels on the two scanning days.  
 
fMRI Data Analysis 
 The fMRI data from both scanning sessions (HT and placebo) were 
preprocessed and analyzed using the SPM8 software (Wellcome Department of 
Cognitive Neurology, London, UK), implemented in Matlab 7.7 (The MathWorks, Natick, 
USA).  
 The four initial scans were discarded to only use data acquired during steady 
state magnetization. First, images were corrected for spatially realigned to the first image 
from the first session using a six-parameter, rigid-body transformation, unwrapped to 
correct for geometric distortions. Inhomogeneities distortions-related correction maps 
were created with fieldmap SPM toolbox, using the phase of non-EPI gradient echo 
images measured at two echo times (5.19 ms for the first echo and 9.95 ms for the 
second). Using the Mazaika approach, sequences with significant scan-to-scan motion 
artifact greater than 0.5 mm/TR or a variation in global intensity greater than 1.3% were 
considered corrupted and corrected using the linear interpolation algorithm of the 
ArtRepair SPM toolbox 1. The overall percentage of TRs removed for task switching and 
control condition was respectively 5.6% and 6.15% (overall 6%). No significant 
differences in the percentage of TRs removed were observed between whether task 
switching and control conditions or between treatment and placebo. For each participant, 
T1-weighted anatomical images were coregistered to the mean EPI, and segmented into 
white and gray matter. Then, grey matter was normalized using standard Montreal 
Neurological Institute (MNI) space template conforming to the Talairach orientation 
system 2  by applying a 12-parameter affine transformation followed by a nonlinear 
warping 3. The computed transformation parameters were, then applied to all of the 
functional images, interpolated to a final voxel size of 3×3×3 mm3. Finally, an equivalent 
spatial smoothing of 8 mm full width at half maximum (i.e., FWHM) Gaussian kernel was 
applied. 
 A random-effect, epoch-related statistical analysis was performed with a two-
level procedure. At the single-subject level, statistical parametric maps were computed 
from fMRI time series as a block design using a separate general linear model for each 
subject and each session. A set of boxcar functions, modeling the duration of each 
	 3	
conditions (Task A, Task B and Task Switching) separately, was convolved with a 
synthetic hemodynamic response function lasting 78 seconds. The data were high-pass 
filtered (128 s cutoff) to remove low-frequency drifts and serial correlations were 
accounted for by an autoregressive model of the first order. Contrast images were 
calculated for each participant in both hormonal treatment sessions to compare brain 
activity during task switching relative to the control condition. 
 The first levels maps were then submitted to a second level analysis in which 
subjects were treated as a random effect, using a flexible factorial model with subjects, 
hormonal state (placebo, HT) and conditions (task switching and control) as factors. 
First, we investigated the resulting statistical maps for the comparison between task 
switching relative to control, regardless the hormonal state (i.e. task switching > Tasks 
(A+B)/2). Subsequently, we directly compared the two hormonal states (HT compared to 
placebo) during task switching relative to control, using a flexible factorial design with 
hormonal state, task switching and control conditions as factors. In all our comparisons, 
we used a threshold of p<0.001 uncorrected. 
 
Activations localization and reported statistics 
 Coordinates tables are given within the framework standardized stereotaxic brain 
area atlas of Talairach and Tournoux 2 and list all the regions reaching a statistical 
significant level with a voxel-wise threshold of p < 0.001, uncorrected. Anatomic labeling 
of activated regions was performed using Anatomy and WFU PickAtlas SPM toolboxes. 
Moreover, a small volume correction (SVC) analysis was performed with a Family Wise 
Error (FWE) corrected significance threshold of p<0.05, in a 10-mm radius sphere 
centered on the dlPFC [x, y, z=42, 38, 28], ACC [x, y, z=4, 8, 48] and right ventro-lateral 
prefrontal cortex [x, y, z=30, 34, 15], based on coordinates taken from meta-analyses on 
task-switching 4,5. 
 
Region Of Interest Analysis 
 Regions Of Interest (ROI) were used to determine mean beta weights for each 
condition in the two hormonal states. Regions of interest were defined functionally from 
the prefrontal activity observed when averaging the whole-brain analyses taken from two 
hormonal states and conducted with the extension of SPM MarsBaR 
(http://marsbar.sourceforge.net/). For HT compared to placebo during task switching 
relative to control, the functional clusters of interest were the dorsolateral prefrontal 
cortex and	the inferior frontal junction/anterior insula bilaterally. For the anterior cingulate 
cortex, betas values were extracted on peak-voxel activity. In the statistical comparison 
between placebo and HT, the functional ROI was in the right anterior medial prefrontal 
cortex. Figures 5 and Supp. Mat 1 show the parameter estimates obtained from GLM1 in 
each ROI. Note that no statistical test was performed on these parameter estimates 
because the ROI analysis is not independent from the whole-brain analysis. 
 
 The ROI analyses in the left and right pre-SMA (Figure S2) were performed 
using anatomic ROIs independently created from the WFU PickAtlas SPM toolbox. The 
betas estimated were extracted from the task switching > control comparison and 
compare using a paired t-test (two-tails). 
 
 
  
	 4	
Supplementary Results 
Assessment of women quality of life under HT and placebo  
 On the first day of the visit and at the end of each week of our 16 weeks study, 
women filled a simplified Women Health Questionnaire (WHQ) to assess 9 domains of 
symptom experience relevant to the menopause and associated with psychosocial 
factors, including depressive mood, somatic symptoms, memory/concentration, 
vasomotor symptoms, anxiety/fear, sexual behavior, sleep problems, menstrual 
symptoms and attractiveness. The scores obtained for the 9 domains assessed after the 
8 weeks under HT and after the 8 weeks under placebo were averaged separately for 
each subject (Fig.2S). A paired t-test analysis did not show significantly difference 
between HT and placebo (all: P > 0.05), suggesting that larger cohort 
neuropsychological studies is needed to ensure sufficient power to observe differences 
between treatment types. 
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Supplementary Figures 
 
Figure S1. Anterior medial prefrontal cortex engaged by the comparison 'control >task 
switching', regardless of treatment type. (A) In the comparison 'control > task switching', 
a relative deactivation was observed in a large anterior medial frontal cortex region 
(Display threshold: voxel-wise p<0.001, uncorrected; cluster-wise p<0.05, FWE 
corrected). (B) Direct statistical comparison, between Placebo and HT in 'control> task 
switching', showed higher BOLD responses in the right anterior medial prefrontal cortex 
(Display threshold, p<0.005, uncorrected). The activation maps are overlaid on coronal 
sections of a structural template MRI. The color bar indicates t values.  
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Figure S2. Evaluation of women's quality of life after 8 weeks under placebo and after 8 
weeks after HT. Scores of the 9 assessed domains ((1) depressed mood, (2) somatic 
symptoms, (3) memory/concentration, (4) vasomotor symptoms, (5) anxiety/fears, (6) 
sexual behavior, (7) sleep problems, (8) menstrual symptoms, (9) attractiveness) of the 
Women's Health Quality of life questionnaires assessed all along the placebo and HT 
period reported for all subjects after averaging their individual scores.” 
 
Table S1. Estradiol level in pmol/L (running order) after placebo and hormone therapy. 
 
 
 Placebo  Hormone therapy  
   Subject 1 19 (day 1) 236 
Subject 2 57 (day 1) 200 
Subject 3 19 82 (day 1) 
Subject 4 19 205 (day1) 
Subject 5 19 (day 1) 228 
Subject 6 19 (day 1) 104 
Subject 7 27 28 (day 1) 
Subject 8 21 212 (day 1) 
Subject 9 19 109 (day 1) 
Subject 10 26 74 (day 1) 
Subject 11 19 (day 1) 102 
Subject 12 19 (day 1) 132 
   	
 Table S2. Brains regions showing increased activity after placebo compared with hormone 
therapy during task switching blocks relative to control. 
Placebo > Hormone therapy 
Anatomical Structure  
(Broadmann's area) x y z T value 
Frontal 
     Left Superior frontal gyrus (BA 8) -18 20 46 4.85 
 Right Superior frontal gyrus (BA 10) 18 56 22 4.84 
 Left Middle frontal gyrus (BA 6) -27 8 49 3.64 
 Right Middle frontal gyrus (BA 11) 21 44 -11 4.83 
 Left Inferior frontal gyrus (BA 45) -42 44 4 4.85 
 Right Inferior frontal gyrus (BA 45) 54 26 25 4.36 
 Left Superior Medial frontal gyrus (BA 32) -12 35 37 4.53 
 Right Superior Medial frontal gyrus (BA 10) 9 62 19 3.39 
 Left Paracentral lobule -9 -34 55 3.4 
 Right Paracentral lobule (BA 4) * 12 -31 64 4.25 
 Right Precentral gyrus (BA 4) 36 -19 49 3.87 
 Right Putamen (BA 47) * 24 23 -5 4.8 
 Left SMA (BA 6) -12 2 64 3.5 
Parietal     
 Left Superior parietal lobule (BA 5) * -18 -55 61 6.02 
 Right Superior parietal lobule (BA 5) * 21 -52 58 5 
 Left Inferior parietal lobule (BA 2) -54 -31 37 3.86 
 Left Postcentral gyrus (BA 5) * -15 -46 70 5.16 
 Right Postcentral gyrus (BA 3) 48 -22 40 3.99 
 Left Supramarginal gyrus (BA 2) -60 -28 37 3.81 
 Precuneus * -6 -64 28 4.67 
 Left Angular (BA 22) * -57 -58 25 4.26 
 Right Angular (BA 40) 54 -49 28 3.41 
Occipital     
 Left Superior occipital gyrus (BA 19) -18 -82 22 3.68 
 Right Superior occipital gyrus (BA 18) * 24 -88 16 5.65 
 Left Middle occipital gyrus (BA 18) -21 -97 -2 4.11 
 Right Middle occipital gyrus (BA 19) * 30 -67 4 6.51 
 Right Inferior occipital gyrus (BA 19) * 51 -76 -2 4.93 
 Right Calcarine gyrus (BA 18) * 24 -97 1 4.84 
 Left Cuneus (BA 19) -12 -82 31 3.94 
 Right Lingual gyrus (BA 18) 6 -64 4 3.56 
Temporal     
 Right Superior Temporal Gyrus (BA 22) 57 -16 -5 3.79 
 Left Middle temporal gyrus (BA 21) * -45 -52 16 5.34 
 Right Middle temporal gyrus (BA 21) * 60 2 -20 6.21 
 Right Inferior temporal gyrus (BA 37) * 51 -55 -14 5.04 
 Right Fusiform (BA 19) * 36 -70 -20 5.72 
Cerebellum     
 Right Anterior lobe (BA 30) * 18 -37 -23 4.89 
 Left Posterior lobe (BA 19) * -6 -76 -32 5.42 
 Right Posterior lobe * 21 -76 -32 5.25 
 Right Vermis * 6 -49 1 4.46 
Cingulate cortex     
 Left Posterior cingulate (BA 23) * -6 -49 22 7.02 
 Left Middle cingulate cortex -12 -40 52 3.74 
Hippocampus     
 Left Hippocampus(BA 35) -18 -13 -14 3.54 
 Right Hippocampus (BA 37) * 24 -40 4 4.78 
Thalamus     
 Right Thalamus * 9 -19 19 5.85 
Insula     
 Right Insula (BA 47) * 33 20 -14 3.7 
Pallidum     
 Left Pallidum -12 5 -2 4.58 
Caudate     
 Right Caudate nucleus (BA 25) 9 8 -8 3.63 
*p<0.05 FWE cluster-wise corrected 
